Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
AF Gazdar - Oncogene, 2009 - nature.com
The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and
erlotinib, are reversible competitive inhibitors of the tyrosine kinase domain of EGFR that …
erlotinib, are reversible competitive inhibitors of the tyrosine kinase domain of EGFR that …
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies
G Scagliotti, N Hanna, F Fossella, K Sugarman… - The …, 2009 - academic.oup.com
Background. Recent studies of pemetrexed have identified a predictive role for non-small
cell lung cancer (NSCLC) histology. We further reviewed the differential efficacy of …
cell lung cancer (NSCLC) histology. We further reviewed the differential efficacy of …
First-line gefitinib for patients with advanced non–small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy
A Inoue, K Kobayashi, K Usui, M Maemondo… - Journal of Clinical …, 2009 - ascopubs.org
Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …
Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non–small cell lung cancer patients
Purpose: We aim to develop a digital PCR-based method for the quantitative detection of the
two common epidermal growth factor receptor (EGFR) mutations (in-frame deletion at exon …
two common epidermal growth factor receptor (EGFR) mutations (in-frame deletion at exon …
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck
JSW Stewart, EEW Cohen, L Licitra… - Journal of clinical …, 2009 - ascopubs.org
Purpose To compare survival in patients with recurrent or metastatic squamous cell
carcinoma of the head and neck (SCCHN) treated with gefitinib 250 or 500 mg/day or …
carcinoma of the head and neck (SCCHN) treated with gefitinib 250 or 500 mg/day or …
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an …
DM Jackman, VA Miller, LA Cioffredi, BY Yeap… - Clinical Cancer …, 2009 - AACR
Purpose: The impact of epidermal growth factor receptor (EGFR) and KRAS genotypes on
outcomes with erlotinib or gefitinib therapy continues to be debated. This study combines …
outcomes with erlotinib or gefitinib therapy continues to be debated. This study combines …
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors
KK Wong, PM Fracasso, RM Bukowski, TJ Lynch… - Clinical cancer …, 2009 - AACR
Purpose: The dose-limiting toxicities, maximum tolerated dose, pharmacokinetic profile, and
preliminary antitumor activity of neratinib (HKI-272), an irreversible pan ErbB inhibitor, were …
preliminary antitumor activity of neratinib (HKI-272), an irreversible pan ErbB inhibitor, were …
A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane
D Mandelker, SB Gabelli… - Proceedings of the …, 2009 - National Acad Sciences
Mutations in oncogenes often promote tumorigenesis by changing the conformation of the
encoded proteins, thereby altering enzymatic activity. The PIK3CA oncogene, which …
encoded proteins, thereby altering enzymatic activity. The PIK3CA oncogene, which …
Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non–small-cell lung cancer
Purpose Mutations in the epidermal growth factor receptor (EGFR) kinase domain can
predict tumor response to tyrosine kinase inhibitors (TKIs) in non–small-cell lung cancer …
predict tumor response to tyrosine kinase inhibitors (TKIs) in non–small-cell lung cancer …
Pathogenesis of lung cancer signalling pathways: roadmap for therapies
E Brambilla, A Gazdar - European Respiratory Journal, 2009 - Eur Respiratory Soc
Lung cancer is the major cancer killer worldwide, and 5-yr survival is extremely poor (≤
15%), accentuating the need for more effective therapeutic strategies. Significant advances …
15%), accentuating the need for more effective therapeutic strategies. Significant advances …